Community Health Systems (CYH) Q2 2024 earnings summary

Executive summary

• Net operating revenues for Q2 2024 were $3.14 billion, up 0.8% year-over-year; same-store net revenues increased 4.7% due to higher volumes and reimbursement rates.

• Adjusted EBITDA rose to $387 million from $373 million in Q2 2023, with margin improving to 12.3% from 12.0%.

• Net loss attributable to stockholders improved to $(13) million, or $(0.10) per diluted share, versus $(38) million, or $(0.29) per share, in Q2 2023; adjusted net loss per share was $(0.17) compared to $(0.22) last year.

• Same-store admissions increased 3.0%, adjusted admissions 3.2%, and surgeries 0.6% over a record prior-year quarter, while consolidated admissions declined 2.8% due to divestitures.

• Strategic investments in facilities, technology, and physician recruitment, along with strong outpatient and emergency growth, contributed to results.

Financial highlights

• Six-month net operating revenues reached $6.279 billion, a 0.9% increase year-over-year; same-store revenues up 5.2%.

• Six-month adjusted EBITDA was $765 million, up from $707 million year-over-year.

• Net cash provided by operating activities was $101 million in Q2 and $197 million for the first half, up from $86 million and $91 million, respectively, in 2023.

• Capital expenditures were $88 million for Q2 and $181 million for the first half, tracking toward $350–$400 million for 2024.

• Net loss margin attributable to stockholders improved to -0.4% in Q2 2024 from -1.2% in Q2 2023.

Outlook and guidance

• 2024 net operating revenues projected at $12.5–$12.7 billion; adjusted EBITDA expected between $1.52–$1.6 billion.

• Net loss per diluted share guidance for 2024 is $(0.45) to $(0.30); capital expenditures forecasted at $350–$400 million.

• Net cash from operating activities for 2024 projected at $500–$650 million.

• Q3 is expected to be seasonally soft, with Q4 anticipated as the strongest quarter for EBITDA and cash flow.

• Medium-term goals include mid-single digit net revenue growth, mid-teens adjusted EBITDA margin, positive annual free cash flow, and leverage below 5.5x within 3–5 years.